---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-088461"
form_type: "8-K"
ticker: "TVRD"
cik: "0001346830"
company_name: "Tvardi Therapeutics, Inc."
filed_at: "2026-07-30T11:30:33+00:00"
generated_at: "2026-07-30T11:35:29.744460+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tvardi selects ulcerative colitis as first indication for STAT3 inhibitor TTI-109 after positive Phase 1 data

## Summary
- TTI-109 Phase 1 healthy volunteer study showed placebo-adjusted reductions in Th17 (up to 76%), Tfh (up to 43%), and B cells (up to 71%) implicated in UC.
- Company plans to initiate a Phase 2 study in moderate-to-severe UC in 2027, pending IND clearance and funding.
- TTI-109 is an oral small molecule STAT3 inhibitor designed to address immune dysregulation, inflammation, and proliferation.
- KOL webinar with Dr. Randy Longman scheduled for August 19, 2026, to discuss UC treatment landscape and TTI-109 data.

## SEC filing metadata
- accession: 0001104659-26-088461
- form_type: 8-K
- ticker: TVRD
- cik: 0001346830
- company_name: Tvardi Therapeutics, Inc.
- filed_at: 2026-07-30T11:30:33+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1346830/000110465926088461/0001104659-26-088461-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1346830/000110465926088461/tm2621651d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-088461
- JSON: https://secwatch.observer/filing/0001104659-26-088461.json
- Plain text: https://secwatch.observer/filing/0001104659-26-088461.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.